Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Thorax
; 67(1): 12-8, 2012 Jan.
Article
in En
| MEDLINE
| ID: mdl-21825083
Full text:
1
Database:
MEDLINE
Main subject:
DNA
/
Cystic Fibrosis Transmembrane Conductance Regulator
/
Cystic Fibrosis
/
Benzodioxoles
/
Aminopyridines
/
Mutation
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Thorax
Year:
2012
Type:
Article
Affiliation country:
United States